Pulmonaryhypertensionnews.com1 天
Imaging technique may detect earliest signs of PAH tissue changes
An imaging technique called 18F-FAPI PET may be able to detect early signs of changes in blood vessel tissues in PAH, a new ...
Pulmonaryhypertensionnews.com3 天
Adempas helps lower risk in PAH patients, newer risk model confirms
A possibly more precise risk model showed Adempas helped PAH patients at intermediate risk of death arrive at more favorable ...
Pulmonaryhypertensionnews.com8 天
Winrevair regimen balances efficacy, safety in PAH: Analysis
The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...
Pulmonaryhypertensionnews.com12 天
Weight-based Uptravi dosing appropriate for PAH children: Study
A body weight-adjusted regimen of Uptravi dosing for children and adolescents with PAH was deemed appropriate, according to a ...
Pulmonaryhypertensionnews.com12 天
PH can impose physical restrictions, but don’t limit yourself
Living with PH, it's easy to focus on what we can't do instead of what we can. Columnist Colleen Steele's advice? Don't limit ...
Pulmonaryhypertensionnews.com15 天
Phase 2 trial of tiprelestat for PAH receives FDA advice
The U.S. FDA has provided advice for Tiakis Biotech's Phase 2 clinical trial of tiprelestat for pulmonary arterial hypertension, the company states.
Pulmonaryhypertensionnews.com17 天
Alivegen’s ALG-801 named FDA orphan drug for PAH
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALG-801, Alivegen ’s experimental treatment for pulmonary arterial hypertension (PAH).